Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: A randomized, open-label study

References

• Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000;61(Suppl 1):26–32.
   Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, . Evaluation of outcomes with citalopram for depression using measurement-based care in Star*D: implications for clinical practice. Am J Psychiatry 2006;163: 28–40.
   PubMed Web of Science ®Google Scholar
• Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, . Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association For Psychopharmacology Guidelines. J Psychopharmacol 2008;22:343–96.
   PubMed Web of Science ®Google Scholar
• Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, . World Federation Of Societies Of Biological Psychiatry (Wfsbp) Guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007;8:67–104.
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH, Grigoriadis S, Mcintyre RS, Milev R, Ramasubbu R, . Canadian Network For Mood And Anxiety Treatments (Canmat) Clinical Guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26–43.
   PubMed Web of Science ®Google Scholar
• De La Gandara J, Aguera L, Rojo JE, Ros S, De Pedro JM. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand Suppl 2005;32–6.
   Google Scholar
• Horgan D, Dodd S, Berk M. A survey of combination antidepressant use in Australia. Australas Psychiatry 2007;15:26–9.
   PubMed Web of Science ®Google Scholar
• Blier P, Gobbi G, Turcotte JE, De MC, Boucher N, Hebert C, . Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009;19: 457–65.
   PubMed Web of Science ®Google Scholar
• Blier P, Ward He, Tremblay P, Laberge L, Hebert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167:281–8.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Antidepressants. In: Stahl SM, editor. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. 3rd ed. New York: Cambridge University Press; 2008. p 511–66.
   Google Scholar
• Stahl SM. Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 2010;15:79–94.
   Google Scholar
• Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? a literature review of antidepressant combination therapy. J Affect Disord 2005;89:1–11.
   PubMed Web of Science ®Google Scholar
• Lam RW, Wan DD, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002;63:685–93.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am 2007;30:13–29.
   PubMed Web of Science ®Google Scholar
• Lauritzen L, Clemmesen L, Klysner R, Loldrup D, Lunde M, Schaumburg E, . Combined treatment with imipramine and mianserin. A controlled pilot study. Pharmacopsychiatry 1992;25:182–6.
   PubMed Web of Science ®Google Scholar
• Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996;41:201–10.
   PubMed Web of Science ®Google Scholar
• Maes M, Libbrecht I, Van HF, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999;19:177–82.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55:296–300.
   PubMed Web of Science ®Google Scholar
• Mcgrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, . Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A Star*D report. Am J Psychiatry 2006;163:1531–41.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, . Combining medications to enhance depression outcomes (co-med): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168:689–701.
   PubMed Web of Science ®Google Scholar
• Bares M, Novak T, Kopecek M, Stopkova P, Hoschl C. Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice. A retrospective study. Int J Psychiatr Clin Pract 2010;14:303–8.
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC:American Psychiatric Press; 2004.
   Google Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, . The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV And ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22–33.
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(Suppl 13):23–9.
   PubMed Web of Science ®Google Scholar
• Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):10–17.
   PubMedGoogle Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDU Assessment Manual For Psychopharmacology – Revised. US Dept Health, Education And Welfare Publication (Adm) 76-338. Rockville, MD: US Dept Health, Education And Welfare; 1976. p 218.
   Google Scholar
• Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008;63:699–704.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, . Bupropion-Sr, sertraline, or venlafaxine-Xr after failure of SSRIs for depression. New Engl J Med 2006;354:1231–42.
   PubMed Web of Science ®Google Scholar
• Beck AT, Rial WY, Rickels K. Short form of depression inventory: cross-validation. Psychol Rep 1974;34:1184–6.
   PubMed Web of Science ®Google Scholar
• Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006; 12:71–9.
   PubMedGoogle Scholar
• Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Computer-administered clinical rating scales. A review. Psychopharmacology (Berlin) 1996;127:291–301.
   PubMed Web of Science ®Google Scholar
• Baghai TC, Blier P, Baldwin DS, Bauer M, Goodwin GM, Fountoulakis KN, . General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA Section Of Pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2011;261(Suppl 3):207–45.
   Google Scholar
• Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, . Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197–206.
   PubMed Web of Science ®Google Scholar
• Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007;15:581–93.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine Xr in primary care patients with major depressive disorder. Neuropsychobiology 2004;50:57–64.
   PubMed Web of Science ®Google Scholar
• Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, . Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653–61.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189–95.
   PubMed Web of Science ®Google Scholar
• Storosum JG, Van Zwieten BJ, Vermeulen HD, Wohlfarth T, Van Den Brink W. Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues. Eur Psychiatry 2001;16:327–35.
   Google Scholar
• Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649–59.
   PubMed Web of Science ®Google Scholar
• Bazire S. Psychotropic Drug Directory 2010. The professionals’ pocket handbook and aide memoire. Aberdeen: Healthcomm UK Ltd, A Schofield Healthcare Media Company; 2010.
   Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A Star*D report. Am J Psychiatry 2006;163: 1905–17.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Geddes JR, Malvini L, Signoretti A, McGuire H, . Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. J Clin Psychiatry 2008;69:1732–42.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, . Which antidepressants have demonstrated superior efficacy? a review of the evidence. Int Clin Psychopharmacol 2007;22:323–9.
   PubMed Web of Science ®Google Scholar
• Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: Argos Study. Depress Anxiety 2005;22:68–76.
   Google Scholar
• Debattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. A prospective trial of bupropion Sr augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol 2003;23:27–30.
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, . A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A Star*D report. Am J Psychiatry 2006;163:1161–72.
   PubMed Web of Science ®Google Scholar
• Kielholz P, Terzani S, Gastpar M, Adams C. [Treatment of therapy-resistant depressions. results of combined infusion treatment]. Schweiz Med Wochenschr 1982;112: 1090–5.
   Google Scholar
• Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-sr: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004; 65:337–40.
   PubMed Web of Science ®Google Scholar
• Trimble MR. Worldwide use of clomipramine. J Clin Psychiatry 1990;51(Suppl):51–4.
   Google Scholar
• Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, . Medication augmentation after the failure of SSRIs for depression. New Engl J Med 2006;354: 1243–52.
   PubMed Web of Science ®Google Scholar
• Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255:387–400.
   PubMed Web of Science ®Google Scholar
• Ruhe HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006;189:309–16.
   PubMed Web of Science ®Google Scholar
• Bares M, Novak T. The combinations of antidepressant in the acute treatment of resistant depression: a review of randomized trials (in Czech). Psychiatrie 2010;14:28–34.
   Google Scholar
• Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, . Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22:379–87.
   PubMed Web of Science ®Google Scholar
• Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001;103:66–72.
   PubMed Web of Science ®Google Scholar
• Bares M, Novak T, Kopecek M, Stopkova P, Sos P. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study. Neuro Endocrinol Lett 2009;30:723–8.
   Google Scholar
• Keks NA, Burrows GD, Copolov DL, Newton R, Paoletti N, Schweitzer I, . Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? Med J Aust 2007;186:142–4.
   PubMed Web of Science ®Google Scholar
• Thase ME. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry 2011;56: 317–23.
   PubMedGoogle Scholar